Nordea Investment Management
LGND icon

Nordea Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Nordea Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.83M Sell
50,936
-2,789
-5% -$552K 0.01% 450
2025
Q4 		$10.2M Sell
53,725
-7,276
-12% -$1.4M 0.01% 440
2025
Q3 		$10.7M Buy
61,001
+2,341
+4% +$348K 0.01% 437
2025
Q2 		$6.72M Buy
58,660
+28
+0% +$2.99K 0.01% 501
2025
Q1 		$6.17M Buy
58,632
+60
+0.1% +$6.79K 0.01% 496
2024
Q4 		$6.25M Buy
58,572
+2,970
+5% +$336K 0.01% 500
2024
Q3 		$5.48M Sell
55,602
-3,097
-5% -$312K 0.01% 516
2024
Q2 		$4.87M Sell
58,699
-9,629
-14% -$766K 0.01% 533
2024
Q1 		$4.94M Sell
68,328
-643
-0.9% -$47.4K 0.01% 539
2023
Q4 		$4.93M Sell
68,971
-2,381
-3% -$141K 0.01% 524
2023
Q3 		$4.39M Sell
71,352
-796
-1% -$52.4K 0.01% 530
2023
Q2 		$5.27M Buy
72,148
+505
+0.7% +$37.9K 0.01% 507
2023
Q1 		$5.18M Sell
71,643
-2,230
-3% -$159K 0.01% 513
2022
Q4 		$4.88M Sell
73,873
-38,241
-34% -$2.49M 0.01% 527
2022
Q3 		$6.1M Sell
112,114
-377
-0.3% -$22.2K 0.01% 468
2022
Q2 		$6.09M Sell
112,491
-3,475
-3% -$197K 0.01% 482
2022
Q1 		$8.46M Buy
115,966
+1,454
+1% +$105K 0.01% 456
2021
Q4 		$11.2M Sell
114,512
-851
-0.7% -$78.6K 0.01% 386
2021
Q3 		$10.1M Sell
115,363
-1,759
-2% -$136K 0.01% 401
2021
Q2 		$9.59M Buy
117,122
+13,074
+13% +$1.09M 0.01% 408
2021
Q1 		$9.96M Sell
104,048
-2,037
-2% -$193K 0.01% 379
2020
Q4 		$6.58M Buy
106,085
+39,503
+59% +$2.25M 0.01% 448
2020
Q3 		$4.07M Sell
66,582
-65,714
-50% -$4.48M 0.01% 547
2020
Q2 		$9.42M Buy
132,296
+66,443
+101% +$4.21M 0.01% 468
2020
Q1 		$3.03M Buy
65,853
+2,664
+4% +$151K 0.01% 567
2019
Q4 		$4.14M Buy
63,189
+1,663
+3% +$111K 0.01% 605
2019
Q3 		$3.84M Buy
61,526
+20,270
+49% +$1.27M 0.01% 611
2019
Q2 		$2.94M Buy
41,256
+12,808
+45% +$943K 0.01% 674
2019
Q1 		$2.23M Sell
28,448
-1,267
-4% -$96K ﹤0.01% 848
2018
Q4 		$2.52M Sell
29,715
-102
-0.3% -$10.9K 0.01% 787
2018
Q3 		$5.11M Buy
29,817
+4,228
+17% +$637K 0.01% 546
2018
Q2 		$3.31M Sell
25,589
-6,423
-20% -$717K 0.01% 584
2018
Q1 		$3.3M Buy
32,012
+2,756
+9% +$273K 0.01% 538
2017
Q4 		$2.5M Buy
29,256
+1,606
+6% +$139K 0.01% 591
2017
Q3 		$2.35M Buy
27,650
+784
+3% +$62.1K 0.01% 586
2017
Q2 		$2.04M Buy
26,866
+3,361
+14% +$235K 0.01% 576
2017
Q1 		$1.55M Buy
23,505
+5,346
+29% +$352K ﹤0.01% 662
2016
Q4 		$1.15M Buy
18,159
+1,244
+7% +$78.5K ﹤0.01% 712
2016
Q3 		$1.08M Buy
16,915
+8,672
+105% +$637K ﹤0.01% 708
2016
Q2 		$613K Buy
+8,243
New +$612K ﹤0.01% 691

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Nordea Investment Management's LGND Position: Q1 2026 in Review

Nordea Investment Management reduced its Ligand Pharmaceuticals (LGND) stake by 5.2% in Q1 2026, selling an estimated $552K and leaving 50,936 shares worth $9.83M. The position accounts for 0.01% of the portfolio, ranked #450.

Nordea Investment Management first reported a position in LGND in Q2 2016 and has held it in 40 quarters since. The position peaked at $11.2M in Q4 2021. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Nordea Investment Management held 50,936 shares of Ligand Pharmaceuticals worth $9.83M as of Q1 2026.
  • Nordea Investment Management sold 2,789 Ligand Pharmaceuticals shares in Q1 2026, an estimated $552K.
  • Ligand Pharmaceuticals made up 0.01% of Nordea Investment Management's portfolio in Q1 2026, its #450 holding.
  • Nordea Investment Management first reported a position in Ligand Pharmaceuticals in Q2 2016 and has held it in 40 quarters since.
  • Nordea Investment Management's Ligand Pharmaceuticals position peaked at $11.2M in Q4 2021.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Nordea Investment Management's 13F filing for Q1 2026, filed 13 May 2026.